<?xml version="1.0" encoding="UTF-8"?>
<p>After the devastating West African Ebola epidemic in 2013–16, which alone claimed the lives of more than 11,000 people and had a comprehensive economic and social burden estimated at over US$53 billion (or more than $1.8 million per case), the global need for an organization that could finance and coordinate the development of vaccines against EIDs was recognized [
 <xref ref-type="bibr" rid="CR19">19</xref>]. In 2014, although there was no licensed Ebola vaccine available, approximately 15 different vaccines were in preclinical development, including DNA vaccines, virus-like particles (VLPs), and viral vector-based vaccines [
 <xref ref-type="bibr" rid="CR20">20</xref>]. It took a year to initiate field trials of the first Ebola vaccines, many of which had been under development for more than a decade. It became evident that an improved system for the development of vaccines against known and unknown epidemic threats was needed [
 <xref ref-type="bibr" rid="CR21">21</xref>].
</p>
